Single-cell sequencing technology is a milestone technology in the history of biotechnology development, and is currently being used more and more widely in the fields of tumor research, immune research, neurobiological research, and developmental research. Single-cell sequencing technology can discover rare tumor cells and conduct dynamic monitoring, which is helpful for personalized and precise treatment of tumors, and is crucial to the development of precision medicine. In recent years, diverse single-cell technologies have emerged in an endless stream, from various single-omics, to multi-omics, to space-omics. Among them, the space-based multi-omics technology has increasingly become a research hotspot and direction, and was listed by the "Nature" magazine as one worthy of attention in 2022. One of the seven major technologies in the world, "detonating" the scientific research community, the development of space omics has also led to the development of personalized and precision medicine.
According to market statistics, the global single-cell sequencing market is growing at an average annual rate of more than 20%, and is expected to reach US$5.32 billion by 2025. More importantly, single-cell sequencing technology has a potential application market of 200 billion yuan in the field of prenatal and postnatal care and tumor detection. The current domestic market size is close to 10 billion yuan, with a huge prospect. Although single-cell sequencing technology has been applied in almost all fields of life sciences, there are still some problems that need to be solved and improved. Space omics and system detection capabilities need to be broken through, and the gap from research to clinical needs to be bridged. Problems such as difficult selection, high testing cost, complicated testing process, and difficult data interpretation and analysis also need to be solved urgently.
"Explore new cell drugs and talk about the future of immunity", the CGT Asia carnival hosted by Tansi Biotechnology will be held in Guangzhou from October 19th to 20th , RNA-seq Asia 2023 single-cell sequencing and precision medicine forum , 3DCC 2023 3D cells The Cultivation and Organoid R&D Summit and the 4th Asian Cell and Gene Therapy Innovation Summit (Guangzhou Station) of CGT Asia 2023 will be held concurrently. The content of the RNA -seq Asia 2023 Single-Cell Sequencing and Precision Medicine Forum will focus on the frontiers of single-cell multi-omics , Single-cell technology innovation and equipment, single-cell clinical transformation and application, single-cell bioinformatics application and big data tools, single-cell scientific research exploration, etc., aiming to strengthen multi-party communication and resources for scientific research institutions, hospitals and related research companies Information sharing provides an exchange platform to discuss the latest research progress and challenges, display cutting-edge product technologies, and promote the transformation of scientific research results and industrial integration and innovation. Welcome everyone in the industry to come! ( For details, pay attention to "Tansi Biology" )
Conference Highlights
2-day summit & professional technology exhibition, fully focusing on the field of single-cell sequencing
20+ industry leaders share experience insights and application cases
Three summits will be held concurrently: single-cell sequencing and precision medicine + 3D cell culture organoids + cell and gene therapy
80+ high-quality booths display the latest technologies and solutions
Jointly reported by more than 100 media, the most influential CGT industry event in the industry
200+ global gene therapy and cell therapy related companies participated
1500+ domestic and foreign participants
core topic
l Single-cell sequencing innovation from laboratory to clinic
l Spatial multi-imaging technology promotes the next wave of biomedical research revolution
l The important role and mechanism of new subsets of innate immune cells in traumatic brain injury
l The development of spatial transcriptome technology and its application in embryonic development
l Single-cell spatial metatranscriptome sequencing research
l Mass Spectrometry Imaging Spatial Metabolomics and Brain Science Research
l Deep biological significance mining and visualization framework of large-scale single-cell data
l Molecular characteristics of intraocular lymphoma
l Establishment of personalized TCR-T cell therapy
l Develop a computational framework for studying epigenetic heterogeneity
Who should attend?
Universities, research institutes, hospitals, patients, biopharmaceutical companies, preclinical R&D, clinical R&D, vaccine/antibody companies, cell therapy companies, gene therapy companies, research institutes, biotechnology companies, laboratory equipment suppliers, Drug testing, analytical services, manufacturing solution providers (upstream, downstream), life science and analytical equipment, diagnostic and testing equipment, external licensing, protein drug companies, contract service providers (CRO, CMO, CDMO), import and export enterprises , Facilities, Cleanroom Equipment Suppliers, Government Representatives/Trade Organizations, Formulation Machinery, Pharmaceutical Engineering, Legal and Compliance Firms, Drug Delivery System Manufacturers, Third Party Logistics Providers, Automation/Robotics, Cold Chain Packaging Companies, Packaging Machinery , industrial park, laboratory service, laboratory/biochemical/analytical instrument, fine chemical production enterprise, environmental protection, intermediate production enterprise, regulatory service, supply chain, new drug research and development company, consulting company...
Previous participating companies
Ruijin Hospital, Tsinghua University, Tongji University School of Medicine, Graduate School of Chinese Academy of Social Sciences, Second Affiliated Hospital of An Medical University, Fudan Biomedical Research Institute, Central China Normal University, Jinan University, Jiangsu University School of Medicine, Wuhan University Medical Research Institute, Wuhan Bioengineering Academy, Xinjiang Medical University, ASC Therapeutics, AstraZeneca, Aibo Bio, GenScript Vigorous Bio, Angpu Biological, Auscon Biological, Bangyao Biological, Beihai Kangcheng, Binozy, Iron Biological, Lakeside Biological , Bonasia, Santian Pharmaceutical, Shenglin Bio, Panen Bio, Yuanjian Ruckus, Fosun Kate, Gaubb Medical Group, Guite Pharmaceutical, Sinopharm Jinqi, Kangwanda Pharmaceutical, Qilu Pharmaceutical, Huadao Bio, Huaxia Yuanbio, Huida Bio, Huier Bio, Jiyuan Genomics, Kebei Yuanquan, Longxin Bio, Lepu Bio, Longchang Pharmaceutical, Roche, Neophth, Nulunjie Bio, Qilu Pharmaceutical, Merck, Ruizheng Pharmaceuticals, Wisdom Chemicals, Sanofi, Sasselqing, Sunshine Guojian, Sunshine Pharmaceuticals, Sunshine Pharmaceuticals, Henlius, Hengrun Dasheng, Huicun Medical, Kazhi Biological, Laifu Medical, Long Yao Biology, Longyao Bio, Shanghai Cell Therapy Group, Reindeer Bio, Shanghai Pharmaceutical Group, Yinuowei, CSPC, Sudi Medicine, Fangde Menda, Xueji Bio, Yi Mufeng Biology, Yi Mufeng Biology, Weisheng Pharmaceutical, Takeda, Xihu Biological, Xingdehan, Xing Yiang, Xueji Biological, Reindeer Biological, Wuming Junuo, Zhengda Tianqing, etc...
Some past speakers
Wonderful past
Registration consultation: https://s.wcd.im/v/4hglcZ9l/
Official website: https://genetherapy-asia.taaslabs.com/